New pharmacological strategies for the treatment of heart failure

Current Opinion in Investigational Drugs

Volumn 2, Issue 7, 2001, Pages 923-928

  Chin, B S P ^a   Lip, G Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Calcium sensitizer; Endothelin antagonist; Heart failure; Natriuretic peptide; Phosphodiesterase inhibitor

Indexed keywords

AMRINONE; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCIUM SENSITIZER; CANDOXATRIL; CANDOXATRILAT; CARVEDILOL; CYTOKINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; ENOXIMONE; FUROSEMIDE; LEVOSIMENDAN; METOPROLOL; MILRINONE; NESIRITIDE; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN; PIPERANOMETOZINE; PROTEIN INHIBITOR; THALIDOMIDE; TUMOR NECROSIS FACTOR;

CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL MODEL; HEART FAILURE; HEMODYNAMIC PARAMETERS; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; ATRIAL NATRIURETIC FACTOR; CALCIUM; CARDIOTONIC AGENTS; CLINICAL TRIALS; ENDOTHELIN-1; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; MUSCLE PROTEINS; NEPRILYSIN; PHOSPHODIESTERASE INHIBITORS; PYRIDAZINES; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034925894     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Effect of chronic β-adrenergic receptor blockade in congestive cardiomyopathy
2. A randomised trial of low-dose β-blockade therapy for idiopathic dilated cardiomyopathy
3. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
4. Beneficial effects of metoprolol in heart failure associated with coronary heart disease: A randomised trial
5. Effects of carvedilol in patients with congestive heart failure due to ischemic heart disease: Final results from the Australia-New Zealand Heart Failure Research Collaborative Group trial
6. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
7. Double-blind placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial
8. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure
9. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomised trial
10. Effects of controlled-release metoprolol on total mortality, hospitalisations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomised Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group
11. β-Blockers in heart failure: Promising or proved?
12. Effects of enalapril on mortality in severe congestive heart failure. Results of the CONSENSUS
13. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
14. Effects of β-blocker therapy on mortality in patients with heart failure. A systematic overview of randomised controlled trials
15. Brain natriuretic peptide as a novel cardiac hormone in humans
16. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: Effect of stretching
17. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure
18. Natriuretic peptide system in human heart failure
19. Relation of neurohormonal activation to clinical variables and degree of left ventricular dysfunction
20. Brain natriuretic factor: Regional plasma concentrations and correlations with haemodynamic state in cardiac disease
21. N-Terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction
22. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care
23. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure
24. Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by cGMP-mediated process
25. ANF inhibits ACE activity stimulated by endothelin
26. Effects of incremental infusions of atrial natriuretic factor on aldosterone, renin and blood pressure in humans
27. Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells
28. Atrial natriuretic factor, catecholamines and natriuresis
29. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: A randomised, double-blind, placebo-controlled clinical trial. Natrecor Study Group
30. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group
31. Specific inhibitors of endopeptidase 24.11 inhibit the metabolism of atrial natriuretic peptides in vitro and in vivo
32. Renal response to candoxatril in patients with heart failure
33. Effects of renal neutral endopeptidase inhibition on sodium excretion, renal haemodynamics and neurohormonal activation in patients with congestive heart failure
34. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure
35. Effects of UK69578. A novel atriopeptidase inhibitor
36. Increased circulating atrial natriuretic factor concentrations in patients with chronic heart failure after inhibition of neutral endopeptidase: Effects in diastolic function
37. Pharmacology of bipyridine phosphodiesterase III inhibitors
38. Therapeutic strategies to reduce TNF-α mediated cardiac contractile depression following ischemia and reperfusion
39. Therapeutic achievements of phosphodiesterase inhibitors and the future
40. Phosphodiesterase III inhibition or adrenoceptor stimulation: Milrinone as an alternative to dobutamine in the treatment of severe heart failure
41. Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group
42. Acute haemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure
43. Acute haemodynamic effects of a new inotropic agent (OPC-8212) in patients with congestive heart failure
44. Evaluation of a new inotropic agent, OPC-8212, in patients with dilated cardiomyopathy and heart failure
45. A multicenter study of a new inotropic agent, pipernometozine (OPC-8121) in congestive heart failure: Clinical improvement during short-term treatment
46. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. VeST Investigators
47. Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and calcium sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart
48. Calcium sensitising agents in heart failure
49. Effect of pimobendan on exercise capacity in patients with heart failure: Main results from the Pimobendan in Congestive Heart Failure (PICO) trial
50. Cardiac troponin C as a target protein for a novel calcium sensitising drug, levosimendan
51. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan
52. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure
53. Oral levosimendan improves cardiac function and haemodynamics in patients with severe congestive heart failure
54. Endothelium: The axis of vascular health and disease
55. Endothelins: Molecular biology, biochemistry, pharmacology, physiology and pathophysiology
56. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
57. Endothelin antagonists
58. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
59. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease
60. Role of tumor necrosis factor-α in the progression of heart failure
61. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure
62. Anti-EDRF effect of tumor necrosis factor in isolated, perfused rat carotid arteries
63. Tumor necrosis factor down regulates nitric oxide synthase mRNA by shortening its half life
64. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure
65. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α